Wednesday, July 8, 2026

Drug profile · INN

avacopan

avacopan (TAVNEOS) is a c5a anaphylatoxin chemotactic receptor antagonist. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved PMDA: approved Antineoplastic and immunomodulating agents (L04) L04
US status approved
Patents linked 1
Pipeline programs 1
News articles 3
Drug details — avacopan
US status
approved
Class
Antineoplastic and immunomodulating agents (L04)
Route
ORAL
Patents
1
Programs
1
Data quality
0.84

Quick answer

avacopan (TAVNEOS) is a c5a anaphylatoxin chemotactic receptor antagonist. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN avacopan
Brand TAVNEOS
Mechanism C5a anaphylatoxin chemotactic receptor antagonist
Target C5a anaphylatoxin chemotactic receptor 1
Therapeutic class Antineoplastic and immunomodulating agents (L04)
Route ORAL
Formulation CAPSULE
ATC code L04

Mechanism of action

C5a anaphylatoxin chemotactic receptor antagonist

Primary target: C5a anaphylatoxin chemotactic receptor 1

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved
PMDA approved

Recent coverage

Pipeline programs

  1. 20220159 Approved · Amgen · Antineutrophil cytoplasmic antibody-associated vasculitis (A

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)
  1. US 20260027049

    AVACOPAN FORMULATIONS

    Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is avacopan?

avacopan (TAVNEOS) is a c5a anaphylatoxin chemotactic receptor antagonist. Associated with Seqirus (Australia) Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for avacopan?

TAVNEOS is a marketed brand name for avacopan. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of avacopan?

avacopan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.